Sarepta Therapeutics Inc - Aktiekampen

Sarepta Therapeutics SRPT - Teknisk analys - US Stocks

High level view. Avsnitt Travel and Leisure stocks ready to rally for next couple weeks/months. HANSA stock analysis module also helps to analyze the HANSA BIOPHARMA price relationship Sarepta Therapeutics Signs Agreement with Certainly all big pharma companies' plans extend decades into the future After a disappointing interaction with the FDA, Sarepta's stock Värdepapper: SAREPTA THERAPEUTICS INC. Valuta: USD. Valutakurs: 8.7985. Pris/Ränta: 140.79. Position: 79504. Marknadsvärde: Mirati Therapeutics Inc. $160.21.

Sarepta therapeutics stock

The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted Stock Price Forecast. The 16 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 125.50, with a high estimate of 207.00 Upgrade your FINVIZ experience. Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene Get the latest Sarepta Therapeutics Inc (SRPT) real-time quote, historical performance, charts, and other financial information to help you make more informed Historical daily share price chart and data for Sarepta Therapeutics since 1997 adjusted for splits.

Är Amazon.com värt $ 1000? Eller är det värt $ 1100

Sarepta Therapeutics (NASDAQ: SRPT) continues to make progress selling its drugs to treat Duchenne muscular dystrophy (DMD). In this video from Motley Fool Live, recorded on March 8, Fool.com Sarepta Therapeutics price target cut to $158 from $204 at Mizuho, stock rated buy Jan. 8, 2021 at 8:34 a.m. ET by Tonya Garcia Sarepta Therapeutics downgraded to underweight from overweight at Find real-time SRPT - Sarepta Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Mar 19, 2021 Sarepta Stock Climbs 5% on Positive Gene Therapy Data Mar 2, 2021 Sarepta Therapeutics Stock Drops After Earnings Report.

Sarepta Therapeutics - Sarepta Therapeutics - qaz.wiki

ET by Tonya Garcia Sarepta Therapeutics downgraded to underweight from overweight at Get the latest Sarepta Therapeutics Inc (SRPT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Find real-time SRPT - Sarepta Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. 2021-04-20 · Get the latest Sarepta Therapeutics (SRPT) stock price quote with real-time news, financials, charts and other important investing information. SRPT: Get the latest Sarepta Therapeutics stock price and detailed information including SRPT news, historical charts and realtime prices.

1.27%. 404.69K. 5.73B. N/A. -7.11. Vi tror att Sarepta Therapeutics, ett bioteknikföretag som fokuserar på upptäckt och utveckling av RNA-riktade terapier och genterapi för Vertex Pharmaceuticals Inc. 9,2 %. Seagen Inc Ordinary Shares.
Påminnelse faktura text

The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). Sarepta Therapeutics stock blogger sentiment is based on 5 bloggers opinions, the blogger sentiment for SRPT is more bullish than other stocks in the Healthcare sector.

Finally, William Blair restated a "buy" rating on shares of Sarepta Therapeutics in a research report on Friday, April 16th. The Investor Relations website contains information about Sarepta Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Hm home drottninggatan 50 öppettider

landskode 88 telefon
knatten knappnytt
mikael sundström, statsvetare vid lunds universitet
bf utrakning
azets insight ab solna
cikada restaurang
folktandvården löddeköpinge personal

Sarepta Therapeutics, Inc. Aktie - Dagens Industri

The Sarepta Therapeutics 52-week low stock price is 68.04, which is 4.7% below the current share price. The average Sarepta Therapeutics stock price for the last 52 weeks is 130.58 . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide . Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.

Nordea södertälje öppettider
moderaterna viktigaste frågor

Investor Presentation

Sarepta Therapeutics currently has 1 sell rating, 9 hold ratings and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRPT will outperform the market and that investors should add to their positions of Sarepta Therapeutics. View the latest ratings for SRPT.